Traders should monitor the upcoming 52-week VELA data in Q2 2026 and the BLA submission in H2 2026 as key catalysts. Given the strong durability and superiority over existing therapies, MLTX is well-positioned for positive regulatory and commercial momentum, especially in a high-unmet-need indication with limited treatment options.
Price Chart
Executive Summary
MoonLake Immunotherapeutics announced positive long-term Week 40 results from its Phase 3 VELA-1 and VELA-2 trials of sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa (HS), showing 62% of patients achieved HiSCR75 and up to 32% achieved HiSCR100, with sustained efficacy and no new safety signals. The data reinforce SLK's potential as a best-in-class therapy, outperforming existing IL-17 inhibitors, and support an upcoming BLA submission for HS in H2 2026.
Key Facts
- 62% of patients treated with sonelokimab achieved HiSCR75 at Week 40 across VELA-1 and VELA-2 trials, with up to 32% achieving HiSCR100
- No new safety signals were detected, and discontinuation rates were low
- Sonelokimab outperforms approved IL-17A and IL-17A/F inhibitors, which reported ~40% and ~60% HiSCR75 at one year, respectively
- Detailed results will be presented at the 2026 AAD Annual Meeting by Prof. Alexa Kimball of Harvard Medical School
- BLA submission for HS is expected in H2 2026, with 52-week data anticipated in Q2 2026
Financial Impact
Significant potential upside ahead of BLA submission and 52-week data readout; strong efficacy could position sonelokimab as a leading HS therapy in a $15B market by 2035
Risk Factors
- Regulatory risk: Final BLA approval not guaranteed despite strong data
- Competition: Other IL-17 inhibitors may adjust dosing or positioning to compete
- Commercial execution: As a clinical-stage company, MoonLake lacks a commercial infrastructure and may need a partner
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264203 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $17.23 | awaiting T+60 | — | $11.85 (−31.22%) |
Aug 10, 2026 11w ago | 8-K | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Aug 10, 2026 11w ago | Press Release | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Jul 20, 2026 14w ago | Insider Cluster | $19.05 $10.41 | ▲ +45.35% | ▲ +50.19% | $11.85 (+37.80%) |
Jun 25, 2026 17w ago | 8-K | $19.99 $12.39 | ▲ +38.02% | ▲ +41.87% | $11.85 (+40.72%) |
Jun 23, 2026 17w ago | Press Release | $20.00 $12.20 | ▲ +39.00% | ▲ +42.29% | $11.85 (+40.75%) |
Jun 22, 2026 18w ago | 8-K | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 21, 2026 18w ago | Press Release | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $17.75 $15.01 | ▲ +15.44% | ▲ +19.83% | $11.85 (+33.24%) |
Jun 1, 2026 21w ago | 8-K | $18.82 $15.56 | ▼ −17.32% | ▼ −18.55% | $11.85 (−37.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers